← boardnext 2027-06-30next 2032-10-31
IMNN
Imunondistress 8/10 · high distress / dilution risk$1.590%today-80% from 52w high
Infectious Disease 1
Lead: Ovarian Cancer · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$15M
Runway
1.0 yrs
Shares 1y
+92%
Price & events
-54.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-15.9%
1W
-10.7%
1M
-44.4%
3M
-56.2%
6M
-77.0%
1Y
-90.2%
2Y
-99.2%
5Y
-99.0%
All
Overview
- Market Cap
- $6.68M
- Volume
- 24.55K
- 52 Week Range
- $1.59 – $8.09
- Total Shares
- 4.20M
- Float Shares
- 3.61M
- Short %
- 1.22%
- % Held by Insiders
- 5.08%
- % Held by Institutions
- 11.99%
- RVOL
- 0.14x
- Beta
- 1.95
Pipeline stages · 3 programs
Paclitaxel, Carboplatin, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carb
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IMNN-101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06-30 Estimated 50% readout ~2027-08-14 | Phase 1/2 | Paclitaxel, Carboplatin, Bevacizumab | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | — | recruiting |
| 2032-10-31 Estimated 50% readout ~2033-01-14 | Phase 3 | IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carb | Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | — | recruiting |
| 2025-03-07 | Phase 1/2 | IMNN-101 | SARS CoV 2 Infection | 24 | completed |
Catalyst news & presentations · 4
- 2025-05-22withdrawalImunon requested withdrawal of its S-1 registration statement, abandoning the public offering.SEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 3IMNN-001 · Phase 3 pivotal trial initiationSEC 8-K
- 2025-03-24fda agreementIMNN-001 · FDA aligned on Phase 3 OVATION 3 study design for IMNN-001 in newly diagnosed advanced ovarian cancer.SEC 8-K
- 2024-12-01fda agreementIMNN-001 · Positive Type C CMC meeting with FDA regarding cGMP production for Phase 3 trial and commercialization.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-17Maxim GroupBuy
- 2025-05-19D. Boral CapitalBuy → Hold
- 2025-05-13D. Boral CapitalBuy
- 2025-05-07D. Boral CapitalBuy
- 2025-03-26HC Wainwright & Co.Buy
- 2025-03-24D. Boral CapitalBuy
Competitors — Ovarian Cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- CORTCORCEPT THERAPEUTICS INC$10.0B · D0
- XNCRXencor Inc$1.4B · D4
- VSTMVerastem, Inc.$515M · D5
- ZNTLZentalis Pharmaceuticals, Inc.$334M · D5
- NXTCNextCure, Inc.$16M · D9
- GMABGENMAB A/S— · D1
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-23IMUNON presents ovarian cancer therapy data at AACR conference By Investing.com - Investing.com Canada
- 2026-07-23IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development - GlobeNewswire
- 2026-07-23IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development - GlobeNewswire
- 2026-07-22IMUNON Reports Preliminary Phase II MRD Data As Phase III Ovarian Cancer Trial Advances - insights.citeline.com
- 2026-07-22IMUNON's IL-12 Therapy Breaks Ovarian Cancer Safety Barrier - AllSci
- 2026-07-21Insider Sell: Susan Eylward Sells 2,150 Shares of Imunon Inc (IM - GuruFocus
- 2026-07-21Imunon general counsel Susan Eylward sells $3,830 in stock By Investing.com - Investing.com Nigeria
- 2026-07-21Imunon general counsel Susan Eylward sells $3,830 in stock By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.